39 results on '"Malagola M."'
Search Results
2. P1450: AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCES HIGHER LEVEL OF EXHAUSTED T-CELLS IN DLBCL PATIENTS BEFORE LEUKAPHERESIS FOR CAR-T CELL THERAPY.
3. PB2209: HIGH RISK MYELODYSPLASTIC SYNDROME DEVELOPING IN A PATIENT AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T- CELL THERAPY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA
4. dsDNA from extracellular vesicles (EVs) in adult AML
5. Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?
6. PB2269 PARENTERAL NUTRITION AND ACUTE GVHD IN HEMATOPOIETIC STEM CELLS TRANSPLANTATION: A PROSPECTIVE OBSERVATIONAL COHORT STUDY
7. S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY
8. PS1540 MULTIPARAMETRIC PREDICTIVE SCORE FOR GRAFT VERSUS HOST DISEASE (GVHD) IN PATIENTS SUBMITTED TO ALLOGENEIC STEM CELLS TRANSPLANTATION (SCT)
9. S881 PREGNANCY OUTCOME IN FEMALE PATIENTS WITH CHRONIC MYELOID LEUKEMIA WORLDWIDE: ANALYSIS OF 305 CASES OF THE EUROPEAN LEUKEMIA NET REGISTRY
10. PS997 A NEW BIOMARKER OF RESPONSE TO 5-AZACITIDINE THERAPY IN MDS AND AML PATIENTS: SIRPB1
11. PF404 TUMOR-DERIVED EXOSOMES MAY BE USED AS NEW INFORMATIVE TOOL FOR THE DETECTION OF BONE MARROW RESIDUAL CML LEUKEMIC CELLS ACTIVITY
12. Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation
13. Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment
14. Differences among young adults, adults and elderly chronic myeloid leukemia patients
15. A specific Toll-like receptor profile on T lymphocytes and values of monocytes correlate with bacterial, fungal, and cytomegalovirus infections in the early period of allogeneic stem cell transplantation
16. Targeting oncogene expression to endothelial cells induces proliferation of the myelo-erythroid lineage by repressing the notch pathway
17. Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin
18. 216 Azacitidine low-dose schedule in low-risk myelodysplastic syndromes. Clinical results of a multicenter phase II study
19. Myeloid Sarcoma: The Clinician's Point of View
20. Efficacy of dasatinib in conjunction with α-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia
21. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study
22. Long-term molecular complete remission with IFN-α in Ph+ adult acute lymphoid leukemia patients
23. Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study.
24. P153 Clinical effects of 5-azacitidine five days/monthly schedule in three symptomatic low-risk (IPSS: 0-1) myelodysplastic patients
25. Corrigendum
26. The importance of consistent use of denominators across patient groups in assessing responses in clinical trials - response to Davies & Cavenagh
27. Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia
28. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma
29. Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia
30. Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents
31. Microdose α-interferon shows clinical and antiangiogenic effect in extramedullary myeloid tumor: a case report
32. Molecular monitoring of acute myeloid leukemia associated with inv(16): threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous Complete Remission is likely
33. Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190BCR-ABL-positive acute lymphoblastic leukemia
34. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study
35. Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia
36. Pulsed ATRA as single therapy restores long-term remission in PML-RARα-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study
37. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia – analysis of 848 patients
38. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia
39. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.